Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity

B Zingales - Acta tropica, 2018 - Elsevier
The genetic diversity of Trypanosoma cruzi, the protozoan agent of Chagas disease, is
widely recognized. At present, T. cruzi is partitioned into seven discrete ty** units (DTUs) …

Treatment of Chagas disease in the United States

S Meymandi, S Hernandez, S Park… - … treatment options in …, 2018 - Springer
Abstract Purpose of Review Chagas disease (CD) is endemic to much of Latin America, but
also present in the United States (US). Following a lengthy asymptomatic period, CD …

New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind …

F Torrico, J Gascón, F Barreira, B Blum… - The Lancet Infectious …, 2021 - thelancet.com
Summary Background Current treatment for Chagas disease with the only available drugs,
benznidazole or nifurtimox, has substantial limitations, including long treatment duration and …

Trypanocidal treatment of Chagas disease

JA Pérez-Molina, C Crespillo-Andújar… - … y microbiologia clinica, 2021 - Elsevier
Chagas disease is a neglected parasitosis caused by the protozoan parasite Trypanosoma
cruzi. This infection is present in most Latin American countries, although, due to migratory …

Chagas disease diagnostic applications: present knowledge and future steps

V Balouz, F Agüero, CA Buscaglia - Advances in parasitology, 2017 - Elsevier
Chagas disease, caused by the protozoan Trypanosoma cruzi, is a lifelong and debilitating
illness of major significance throughout Latin America and an emergent threat to global …

Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas …

J Altcheh, L Castro, JC Dib, U Grossmann… - PLoS neglected …, 2021 - journals.plos.org
Nifurtimox is a recommended treatment for Chagas disease, but data from treated children
are limited. We investigated the efficacy, safety and tolerability of nifurtimox administered as …

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas' disease

Y Jackson, B Wyssa, F Chappuis - Journal of Antimicrobial …, 2020 - academic.oup.com
Abstract Background Current options for Chagas' disease treatment are restricted to
benznidazole and nifurtimox. To the best of our knowledge, no study has ever compared …

Review of pharmacological options for the treatment of Chagas disease

F Lascano, F García Bournissen… - British journal of clinical …, 2022 - Wiley Online Library
Chagas disease (CD) is a worldwide problem, with over 8 million people infected in both
rural and urban areas. CD was first described over a century ago, but only two drugs are …

Why hasn't there been more progress in new Chagas disease drug discovery?

AB Vermelho, GC Rodrigues… - Expert Opinion on Drug …, 2020 - Taylor & Francis
Introduction: Chagas disease (CD) is a neglected disease caused by the protozoan parasite
Trypanosoma cruzi. In terms of novel drug discovery, there has been no progress since the …

[HTML][HTML] Challenges in the management of Chagas disease in Latin-American migrants in Europe

B Monge-Maillo, R López-Vélez - Clinical Microbiology and infection, 2017 - Elsevier
Chagas disease is endemic in Latin America. Due to migration the infection has crossed
borders and it is estimated that 68,000–120,000 people with Chagas disease are currently …